ATE499098T1 - Verwendung von parp-1-hemmern - Google Patents
Verwendung von parp-1-hemmernInfo
- Publication number
- ATE499098T1 ATE499098T1 AT06840026T AT06840026T ATE499098T1 AT E499098 T1 ATE499098 T1 AT E499098T1 AT 06840026 T AT06840026 T AT 06840026T AT 06840026 T AT06840026 T AT 06840026T AT E499098 T1 ATE499098 T1 AT E499098T1
- Authority
- AT
- Austria
- Prior art keywords
- parp
- amount
- tumor
- patient
- increase
- Prior art date
Links
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 title abstract 3
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 abstract 6
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 abstract 6
- 229960000977 trabectedin Drugs 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 3
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73953605P | 2005-11-25 | 2005-11-25 | |
| PCT/US2006/061254 WO2007062413A2 (en) | 2005-11-25 | 2006-11-27 | Use of parp-1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE499098T1 true ATE499098T1 (de) | 2011-03-15 |
Family
ID=38068066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06840026T ATE499098T1 (de) | 2005-11-25 | 2006-11-27 | Verwendung von parp-1-hemmern |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090170860A1 (enExample) |
| EP (1) | EP1962843B1 (enExample) |
| JP (1) | JP2009517403A (enExample) |
| AT (1) | ATE499098T1 (enExample) |
| AU (1) | AU2006318226A1 (enExample) |
| CA (1) | CA2630900A1 (enExample) |
| DE (1) | DE602006020335D1 (enExample) |
| ES (1) | ES2361566T3 (enExample) |
| WO (1) | WO2007062413A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| BR0115162A (pt) * | 2000-11-06 | 2003-10-21 | Pharma Mar Sa | Tratamentos antitumorais eficazes |
| GB0117402D0 (en) * | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
| US20080255132A1 (en) * | 2003-11-14 | 2008-10-16 | Eric Rowinsky | Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer |
| PL1827500T3 (pl) * | 2004-10-26 | 2009-09-30 | Pharma Mar Sa | Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743 |
| DK1658848T3 (da) * | 2004-10-29 | 2007-11-26 | Pharma Mar Sa | Formuleringer omfattende ecteinascidin og et disaccharid |
| GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| US9486449B2 (en) | 2007-10-09 | 2016-11-08 | Malka COHEN-ARMON | Cancer therapy |
| EP2207548B1 (en) * | 2007-10-09 | 2013-05-22 | Malka Cohen-Armon | Breast cancer therapy |
| AU2008313634A1 (en) * | 2007-10-19 | 2009-04-23 | Pharma Mar, S.A. | Prognostic molecular markers for ET-743 treatment |
| US8871765B2 (en) | 2010-07-27 | 2014-10-28 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors |
| EP2870140B8 (en) | 2012-07-09 | 2016-09-28 | Lupin Limited | Tetrahydroquinazolinone derivatives as parp inhibitors |
| SG11201503670YA (en) | 2012-12-31 | 2015-07-30 | Cadila Healthcare Ltd | Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
| CN106853252B (zh) * | 2015-12-09 | 2020-03-13 | 江苏恒瑞医药股份有限公司 | 曲贝替定药物组合物及其制备方法 |
| CN108368059B (zh) * | 2016-04-18 | 2022-02-01 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的酞嗪酮化合物及其药物组合物 |
| KR20180097876A (ko) * | 2017-02-24 | 2018-09-03 | 주식회사 온코크로스 | 1,5-이소퀴놀린디올을 포함하는 피부 노화 방지 및 주름 개선용 조성물 |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| EP3960177A1 (en) * | 2020-08-26 | 2022-03-02 | Anturec Pharmaceuticals GmbH | Composition comprising ttf-ngr for use in treating soft-tissue sarcoma |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635677B2 (en) * | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| BR0115162A (pt) * | 2000-11-06 | 2003-10-21 | Pharma Mar Sa | Tratamentos antitumorais eficazes |
| JP4824566B2 (ja) * | 2003-05-28 | 2011-11-30 | エーザイ インコーポレーテッド | Ｐａｒｐを阻害するための化合物、方法、および医薬組成物 |
| GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| US20050187172A1 (en) * | 2003-12-23 | 2005-08-25 | Masferrer Jaime L. | Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia |
| PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
-
2006
- 2006-11-27 CA CA002630900A patent/CA2630900A1/en not_active Abandoned
- 2006-11-27 ES ES06840026T patent/ES2361566T3/es active Active
- 2006-11-27 WO PCT/US2006/061254 patent/WO2007062413A2/en not_active Ceased
- 2006-11-27 DE DE602006020335T patent/DE602006020335D1/de active Active
- 2006-11-27 AT AT06840026T patent/ATE499098T1/de not_active IP Right Cessation
- 2006-11-27 AU AU2006318226A patent/AU2006318226A1/en not_active Abandoned
- 2006-11-27 EP EP06840026A patent/EP1962843B1/en active Active
- 2006-11-27 JP JP2008542534A patent/JP2009517403A/ja active Pending
- 2006-11-27 US US12/094,744 patent/US20090170860A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1962843A2 (en) | 2008-09-03 |
| EP1962843A4 (en) | 2009-08-12 |
| US20090170860A1 (en) | 2009-07-02 |
| WO2007062413A3 (en) | 2007-12-27 |
| JP2009517403A (ja) | 2009-04-30 |
| DE602006020335D1 (de) | 2011-04-07 |
| WO2007062413A2 (en) | 2007-05-31 |
| CA2630900A1 (en) | 2007-05-31 |
| AU2006318226A1 (en) | 2007-05-31 |
| EP1962843B1 (en) | 2011-02-23 |
| ES2361566T3 (es) | 2011-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE499098T1 (de) | Verwendung von parp-1-hemmern | |
| GEP20125565B (en) | Lactam compounds and their pharmaceutical use | |
| MY147393A (en) | Administration of dipeptidyl peptidase inhibitors | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| SG161318A1 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| DOP2002000438A (es) | Inhibidores de la dipetidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes | |
| UY29246A1 (es) | Nuevos compuestos | |
| NO20065368L (no) | Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin | |
| SG164368A1 (en) | Treatment of cancer | |
| TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
| NO20072558L (no) | Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav | |
| ECSP055783A (es) | Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevención de diabetes | |
| ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
| ATE450251T1 (de) | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung | |
| CY1111263T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης | |
| UA103181C2 (ru) | Соединения, которые ингибируют дипептидилпептидазу-iv и фармацевтическая композиция, которая содержит их как активный агент | |
| IL181271A0 (en) | Triazolophthalazine derivatives and pharmaceutical compositions containing the same | |
| DK1654253T3 (da) | Substituerede 3-pyrrolidinindolderivater | |
| BRPI0410467A (pt) | composições e métodos para tratamento de sìndrome respiratória aguda severa (sars) | |
| DK1641803T3 (da) | Thienopyrimidinderivater som kaliumkanalinhibitorer | |
| CL2007001748A1 (es) | Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras. | |
| UA84954C2 (ru) | Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования | |
| DK1781277T3 (da) | Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol | |
| IL183481A (en) | Combinations containing vegf-trap with 5-fluorouracil are useful in the treatment of neoplastic diseases | |
| TW200716204A (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |